Related references
Note: Only part of the references are listed.Update on the causes, investigation and management of empyema in childhood
Woolf Walker et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2011)
Advances in Pneumococcal Disease Prevention: 13-Valent Pneumococcal Conjugate Vaccine for Infants and Children
Peter R. Paradiso
CLINICAL INFECTIOUS DISEASES (2011)
The Changing Epidemiology of Streptococcus pneumoniae Serotype 19A Clonal Complexes
Gregory J. Tyrrell
JOURNAL OF INFECTIOUS DISEASES (2011)
Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age
F. M. Russell et al.
VACCINE (2011)
Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared to Those of a 7-Valent Pneumococcal Conjugate Vaccine Given as a Three-Dose Series with Routine Vaccines in Healthy Infants and Toddlers
Susanna Esposito et al.
CLINICAL AND VACCINE IMMUNOLOGY (2010)
Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed) [Prevenar 13 (R)]
Sean T. Duggan
DRUGS (2010)
Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate Vaccine
Tamara Pilishvili et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Immunogenicity and Reactogenicity of a 13-Valent-pneumococcal Conjugate Vaccine Administered at 2, 4, and 12 Months of Age A Double-blind Randomized Active-controlled Trial
Matthew D. Snape et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2010)
Policy Statement-Recommendations for the Prevention of Streptococcus pneumoniae Infections in Infants and Children: Use of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Pneumococcal Polysaccharide Vaccine (PPSV23)
Joseph A. Bocchini et al.
PEDIATRICS (2010)
Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine
Kristina A. Bryant et al.
PEDIATRICS (2010)
Serotype 19A Is the Most Common Serotype Causing Invasive Pneumococcal Infections in Children
Sheldon L. Kaplan et al.
PEDIATRICS (2010)
Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Infants and Toddlers
Sylvia H. Yeh et al.
PEDIATRICS (2010)
Pharmacoeconomic evaluation of 10-and 13-valent pneumococcal conjugate vaccines
Anderson W. Chuck et al.
VACCINE (2010)
Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States
Jaime L. Rubin et al.
VACCINE (2010)
Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany
Dorothee M. Kieninger et al.
VACCINE (2010)
Pneumococcal disease caused by serotype 19A: Review of the literature and implications for future vaccine development
Ralf Rene Reinert et al.
VACCINE (2010)
Cost effectiveness of pneumococcal vaccination among Dutch infants: an economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines
Mark H. Rozenbaum et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine
Ener Cagri Dinleyici et al.
EXPERT REVIEW OF VACCINES (2009)
Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates
Katherine L. O'Brien et al.
LANCET (2009)
Use of opsonophagocytosis for serological evaluation of pneurnococcal vaccines
S Romero-Steiner et al.
CLINICAL AND VACCINE IMMUNOLOGY (2006)
Streptococcus pneumoniae: Description of the pathogen, disease epidemiology, treatment, and prevention
AE Bridy-Pappas et al.
PHARMACOTHERAPY (2005)
Conjugated heptavalent pneumococcal vaccine
VB Pai et al.
ANNALS OF PHARMACOTHERAPY (2002)
Share Paper
